Category Archives: Genetic Engineering

Public release date: 10-Jun-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 10, 2013The Genetics Policy Institute (GPI) and Mary Ann Liebert, Inc., publishers have announced that the 2013 World Stem Cell Report will be published as a special supplement to the peer-reviewed journal Stem Cells and Development. Dr. Graham Parker and Bernard Siegel will serve as Co-Editors-in-Chief, joined by Rosario Isasi (McGill University) as Managing Editor.

It was also announced that Mary Ann Liebert, Inc., publishers and Genetic Engineering & Biotechnology News (GEN), a Liebert publication, will become joint platinum media sponsors of the GPI's 2013 World Stem Cell Summit that will take place at the Manchester Grand Hyatt San Diego, December 4 in San Diego, CA.

Bernard Siegel, Executive Director of GPI and Founder and Co-chair of the Summit said, "We are proud to partner with Graham Parker and the skilled editorial team at Stem Cells and Development to publish our annual Report. The Journal's extensive audience, combined with the reach of the community attending and supporting the World Stem Cell Summit, will allow our readership to expand exponentially. We will continue to provide an array of specialized articles offering unique insights of leading policy-makers, regulators, and experts in law, ethics, advocacy, industry, and philanthropy from countries, regions, and states. The Report fills a critical unmet need by providing a global framework for all stakeholders."

Mary Ann Liebert, publisher & CEO of both Stem Cells and Development and GEN stated, "We are delighted to be working with a key thought leader and senior statesman for the field, Bernie Siegel, and his GPI team on this important collaboration. The World Stem Cell Report delivers an orbital and unique viewpoint, with content that is timely, comprehensive, and direct. We are proud to add this important annual publication to our many journals that intersect the world of regenerative medicine."

GEN Editor-in-Chief John Sterling stated, "The World Stem Cell Summit is the critical global meeting, providing the best opportunity for the GEN community to participate in the world of regenerative medicine. Our platinum media sponsorship allows GEN readers, both in print and online, and advertisers to have a front row seat to listen and learn from the top experts on the very dynamic and expertly conceptualized Summit platform."

The Report will be made available to all subscribers of Stem Cells and Development and complimentary to attendees of the World Stem Cell Summit. The Summit program delivers on the "big picture" featuring 170+ prominent scientists, business leaders, regulators, policy-makers, advocates, economic development officers, experts in law and ethics, and visionary gurus who will discuss the latest scientific discoveries, business models, legal and regulatory solutions, and best practices. The Summit is expected to attract attendees from more than 40 nations.

###

About Mary Ann Liebert, Inc., publishers

See the original post here:
World Stem Cell Summit to be presented by Genetics Policy Institute, Mary Ann Liebert, Inc., and Genetic Engineering ...

MADISON, Wis., June 5, 2013 /PRNewswire/ --Cellular Dynamics International (CDI) today announced that it has expanded its MyCell Products line, offering access to a number of human disease models and licensing key genetic engineering patents from Life Technologies and Sigma-Aldrich. CDI's MyCell Products include custom cell products manufactured using induced pluripotent stem cell (iPSC) technology to make stem cells or differentiated cells from any individual, including those with diseases of interest to pharmaceutical and academic researchers.

CDI's MyCell Products now offer access to a number of disease models, including cardiomyopathies and arrhythmias, vision disorders, neurological disorders, and muscular dystrophies. In addition, the company is actively working on expanding its disease model offering, currently working on additional disease models for neurodegenerative disorders and drug-induced liver injury (DILI).

Within the MyCell Products line, CDI maintains the iPSC line of each of the disease models, enabling customers to request manufacture of differentiated cells, such as cardiomyocytes, neurons, hepatocytes, and endothelial cells, for their discovery research.

In addition, CDI has licensed Life Technologies' GeneArt Precision TALs (TALENs) and Sigma's CompoZr ZFN technologies, which act like genomic scissors to cut DNA in a precise location. These nuclease technologies facilitate efficient genomic editing by creating double-stranded breaks in DNA at user-specified locations, stimulating the cell's natural repair process and enabling targeted gene insertions, deletions, or modifications. CDI will use the TALENs and ZFN technologies to perform genetic engineering specified by the customer, for example to introduce or correct a specific mutation, thus creating human disease models and isogenic controls.

"This expansion of the MyCell Products line is the next step in our growing disease-in-a-dish portfolio and allows our customers more ready access to diseases of interest from our growing catalog of iPSCs," said Chris Parker, CDI chief commercial officer. "Through the MyCell Products line, researchers can now access human disease models either through creation of iPSC-derived cells directly from a patient, or through inducing a disease state via use of these TALEN or ZFN technologies."

Bob Palay, CDI chief executive officer, said, "CDI's commercial goal has been to provide access to human cells that reproduce human biology, and we see both of these developments as steps toward achieving that goal. We're pleased to license these nuclease technologies from Life Technologies and Sigma-Aldrich, and the combination of these nuclease technologies with CDI's iPSC-derived cells creates a new, powerful tool to better understand and target human disease."

About Cellular Dynamics International, Inc.Cellular Dynamics International, Inc. (CDI) is a leading developer of stem cell technologies for in vitro use in drug discovery, toxicity testing and chemical safety, in vivo and cell-based therapeutic research and stem cell banking. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual's stem cell line created from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. CDI's headquarters are located in Madison, Wisconsin, with a second facility in Novato, California. See http://www.cellulardynamics.com.

Follow us on Twitter @CellDynamics or http://www.twitter.com/celldynamics

Read the original post:
Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents

When scientists Phillipe Horvath and Rodolphe Barrangou set out to find a better way to make yogurt, they didn't expect to stumble across one of the future's most promising discoveries: a super protein that can accurately cut DNAand could perhaps revolutionize genetic engineering.

The protein, called Cas9, can be exploited to snip strands of DNA in exactly the place researchers want. It doesn't make genetic engineering easy, but does make it much, much easieras it allows researchers to splice sequences of DNA together affordably, with unprecedented accuracy.

So how does it work? Well, Cas9 was found last year to join forces with bacteria in such a way that, combined, they home into viruses and kill them by cutting their DNA at specific, targeted points. That's interestingin fact, it made it a prime candidate for making yogurt production more efficient.

But what's more interesting is that Cas9 can be paired with any string of RNAstrings of molecules not unlike DNA which code and regulate gene expressionto target a matching piece of DNA and snip it with incredible accuracy. Kind of like a pair of tiny, custom DNA scissors. That's not interestingthat's amazing.

Now, though, reports Forbes, the world of biology is swarming over Cas9 and the possibilities it affords. George Church of Harvard University explains:

"It is spreading like wildfire from everyone who knows about it and it certainly is very tantalizing. It's easy to get in and start doing lots of experiments."

The embrace of Cas9 could bring with it massive advances, then. Not least the ability to study genetics in ways never before possible. Forbes explains:

[S]ay there are three changes in the DNA in or around a gene that might cause a disease. Right now, it's hard to study them directly. But now, Church says, you could take a cell from a person who has already had their DNA sequenced, as he is doing with his Personal Genome Project. Then you'd create what's known as an induced pluripotent stem cell, a cell that behaves much like one in an embryo. After that, you could use Cas9 to change each of those DNA spelling changes.

There is, of course, still a long way to gothis research is being conducted in Petri dishes right now, not living creaturesbut it's a long time since a single protein had the entire world of biology so excited. It's only a matter of time before something major comes of it; not bad, for a protein which was originally discovered to make better yogurt. [Forbes, Science]

More here:
The Super Protein That Can Cut DNA and Revolutionize Genetic Engineering

Ramble: Simelweis Taboo
I just don #39;t understand narrowmindedness. I don #39;t understand the stubborn refusal to face reality with integrity. I don #39;t understand cowardice. We each have only one life. Why squander it on timidity, prejudice and just so stories? Video referenced: "Taboos of Science" scishow youtu.be " Published on Jul 30, 2012 Hank discusses some of the taboos which have plagued scientific inquiry in the past and a few that still exist today. Like SciShow? http://www.facebook.com Follow SciShow: http://www.twitter.com References: dft.ba This video contains the following sounds from Freesound.org: "grim fart.wav" by Walter_Odington "Toilet Flush.wav" by tweeterdj science, scishow, taboo, society, culture, research, study, ignaz semmelweis, germ theory, disease, louis pasteur, antiseptic, social norms, semmelweis reflex, dean radin, noetic science, stem cell, chimaera, human cloning, clone, dolly, sheep, ethics, religion, panayiotis zavos, synthetic biology, genetic engineering, biology, genetics, mental health, gender identity, gender dysphoria, sexual orientation, physics, archaeology, human remains, spirituality, consciousness, poop, toilet, sanitation"From:rriverstone1Views:39 5ratingsTime:15:28More inPeople Blogs

View post:
Ramble: Simelweis Taboo - Video

Genetic Engineering Of Mesenchymal Stem Cells
ll4.me Genetic Engineering Of Mesenchymal Stem Cells 1. Mesenchymal Stem Cell Engineering and Transplantation: An introduction; F. Aerts, G. Wagemaker- 2. Establishment and Transduction of primary human Stromal/Mesenchymal Stem Cell Monolayers; T. Meyerrose, I. Rosova, m. Dao, P. Herrbrich, G. Bauer, JA Nolta- 3. Gene Expression Profiles of Mesenchymal Stem Cells; DG Phinney- 4. In Vivo Homing and Regeneration of freshly isolated and culture Murine Mesenchymal Stem Cells; RE Ploemacher- 5. Non-human primate models of Mesenchymal Stem Cell Transplantation; SM Devine, R. Hoffman- 6. Engineering of Human Adipose-derived Mesenchymal Stem-like Cells; JK Fraser, M. Zhu, B. Strem, MH Hedrick- 7. Uncommitted Progenitors in Cultures of Bone Marrow-derived Mesenchymal Stem Cells; JJ Minguell, A. Rices, WD Sierralta- 8. Bone Marrow Mesenchymal Stem Cell Transplantation for Children with severe Osteogenesis Imperfecta; EM Horwitz, PL Gordon- 9. Clinical Trials of Human Mesenchymal Stem Cells to support Hematopoietic Stem Cell Transplantation; ON Ko EAN/ISBN : 9781402039591 Publisher(s): Springer Netherlands Discussed keywords: Stammzelle Format: ePub/PDF Author(s): Nolta, Jan A. 1. Mesenchymal Stem Cell Engineering and Transplantation: An introduction; F. Aerts, G. Wagemaker- 2. Establishment and Transduction of primary human Stromal/Mesenchymal Stem Cell Monolayers; T. MeyerFrom:jonibishop696Views:0 0ratingsTime:00:12More inPeople Blogs

Original post:
Genetic Engineering Of Mesenchymal Stem Cells - Video

Public release date: 16-Nov-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, November 15, 2012Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and a risk for serious disease in liver transplant recipients. Molecular tests that can identify early protein markers produced by EBV may have value for diagnosing active infection. The benefits of this diagnostic approach in patients with mononucleosis and in EBV-infected transplant patients are evaluated in an article published in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.

Andrea Crowley, Jeff Connell, Kirsten Schaffer, William Halla, and Jaythoon Hassan, University College Dublin and St. Vincent's University Hospital, Dublin, Ireland, compared three immunoassay methods for detecting antibodies produced by the body in response to EBV infection and the presence of proteins that comprise the EBV early antigen complex. The researchers determined which of the diagnostic tests could better predict EBV infection in patients with mononucleosis or in immunosuppressed adult liver transplant recipients. The article "Is There Diagnostic Value in Detection of Immunoglobulin G Antibodies to the EpsteinBarr Virus Early Antigen?" presents the complete methodology and results of this study.

"Having the ability to predict the risk of developing EBV-induced lymphoproliferative disorders after a transplant has important consequences for patient care, as it would allow for prompt therapy and could potentially decrease patient mortality," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

See original here:
Is the detection of early markers of Epstein Barr virus of diagnostic value?

Public release date: 13-Nov-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, November 12, 2012--Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site. Effective therapy for metastatic cancer requires a combination of treatments, and the benefits of adding radionuclide therapy are explored in three studies published in Journal of Clinical Investigation, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the Journal of Clinical Investigation website.

"The preliminary therapeutic results reported in these case studies using radionuclide multimodality approaches are encouraging," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham. "The outcomes described in these small, single center studies must be confirmed in larger trials before they can be translated into widespread oncology practice."

J. Harvey Turner, MD, FRACP, The University of Western Australia, Fremantle, coauthored two of the case studies and, in the Perspective article "Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control," he states that the synergistic effects that can be achieved by combining chemotherapy and radionuclides "has the potential to enhance efficacy and minimize toxicity." Although advanced forms of lymphoma and neuroendocrine tumors are usually incurable, multimodal treatment approaches may be able to stop or slow tumor progression, achieve durable remission, prolong patient survival, and improve their quality of life.

###

Paul Kruger, Julian Cooney, and J. Harvey Turner report that more patients survived longer and were free of disease when a radioimmunotherapeutic agent was added to their treatment regimen in the article "Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma."

Phillip Claringbold, Richard Price, and J. Harvey Turner added a lutetium-177 labeled peptide to the therapeutic regimen of a group of patients with advanced neuroendocrine cancer and described substantially improved tumor control rates with no significant side effects. They report their findings in "Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors."

About the Journal

Journal of Clinical Investigation, published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham, and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Journal of Clinical Investigation is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways.

Here is the original post:
Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease?

Public release date: 17-Oct-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, October 17, 2012SELEX is a rapid, efficient, and iterative high-throughput method for screening large libraries of molecules to identify those with the potential to be developed as drug compounds or research tools. Advances in SELEX technology that have enabled screening in live cells, called Cell-SELEX, are explored in a comprehensive Review article published in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. The article is available free on the BioResearch Open Access website.

Cell-SELEX uses live cells as targets for binding of molecules called aptamers, comprised of short chains of nucleic acids. Aptamers share many of the qualities that have made antibodies such successful drugs, but offer additional advantages such as stability, short length, and ease of manufacturing. Shoji Ohuchi, University of Tokyo, Japan, examines the ongoing progress in developing and refining this useful process for drug compound screening in the Review article "Cell-SELEX Technology."

"This review summarizes the progress and application of Cell-SELEX technology, providing an excellent resource for beginners to the field and experts alike," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Assay and Drug Development Technologies, Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. website.

Visit link:
Progress in Cell-SELEX compound screening technology reviewed in BioResearch Open Access

3D Biomatrixs Perfecta3D Hanging Drop Plates, which are easy-to-use 96- and 384-well plates for controllable three-dimensional (3D) spheroid culture, were recently featured in several prominent life science and biotechnology journals and websites: Bioscience Technology, The Scientist, Biocompare, and Genetic Engineering and Biotechnology News.

Ann Arbor, MI (PRWEB) September 25, 2012

The Hanging Drop Plates, which allow for controllable 3D spheroid or embryonic stem cell cultures in a well plate format, simplify and streamline spheroid formation, culture, and subsequent testing of the 3D cellular constructs without the aid of coatings or matrices. Such cultures grown in Perfecta3D Hanging Drop Plates allow researchers to easily mimic tissue metabolic and proliferative gradients, capture complex cell-matrix and cell-cell interactions, conduct co-cultures, and monitor cell growth easily and regularly.

In its August issue, Bioscience Technology, a print and online biotechnology magazine, spotlights the Perfecta3D 96-Well Hanging Drop Plates as an Editors Choice technology for new innovative products.

The Scientist, a professional print and online life science magazine that focuses on research news and applications, included the Perfecta3D Hanging Drop Plates in an article in its September 1 issue titled Enter the Third Dimension. The article reviews five innovative tools for 3D cell culture. Of the five tools, the Hanging Drop Plates are the only technology that does not force cell interaction with surfaces or matrices, and also the only technology described as ready for high throughput and automation for drug discovery. The article also quotes University of Michigan Professor Shuichi Takayama, the inventor of the Hanging Drop Plates.

Biocompare, an online resource for life science product information and new technologies, featured the Perfecta3D Hanging Drop Plates in a September 18 article titled, Research Tools for Three-Dimensional Cell Culture. The article describes 3D cell culture technologies in the areas of scaffold-free plates, scaffolds, gels and extracellular matrices, and bioreactors. 3D Biomatrix CEO, Laura Schrader, was quoted in the article.

3D Biomatrix published a Tech Note in the September 15 issue of Genetic Engineering and Biotechnology News titled, 3D Spheroid Models Enter Screening Toolbox. Genetic Engineering and Biotechnology News is a prominent biotechnology newsletter. The Tech Note describes the Perfecta3D Hanging Drop Plates, their applications, and published data in drug testing and co-cultures.

The recent prevalence of articles focusing on 3D cell culture tools demonstrates the growing number of researchers and companies recognizing the importance of 3D cell culture, says Schrader. We are delighted to be included in these articles, as it demonstrates that the Perfecta3D Hanging Drop Plates are becoming prolific on the market because they are easy to adopt and offer a realistic 3D environment.

More information on the Perfecta3D Hanging Drop Plates and direct links to the articles featuring the plates can be found on the 3D Biomatrix website.

Meghan Cuddihy 3D Biomatrix 734.272.4688 Email Information

The rest is here:
3D Biomatrix’s Perfecta3D® Hanging Drop Plates Featured in Prominent Life Science Journals

Public release date: 21-Aug-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 21, 2012For the millions of people worldwide with type 1 diabetes who cannot produce sufficient insulin, the potential to transplant insulin-producing cells could offer hope for a long-term cure. The discovery of a marker to help identify and isolate stem cells that can develop into insulin-producing cells in the pancreas would be a critical step forward and is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the BioResearch Open Access website (http://www.liebertpub.com/biores).

Pancreatic stem cells, the precursors of insulin-producing cells, have not yet been identified in humans or animals, and there is much debate about where they may reside. Ivka Afrikanova, Ayse Kayali, Ana Lopez, and Alberto Hayek, University of California, San Diego, CA, have identified a biochemical markerstage-specific embryonic antigen 4 (SSEA4)that they propose can be used to identify and purify human pancreatic stem cells. The article "Is Stage-Specific Embryonic Antigen 4 a Marker for Human Ductal Stem/Progenitor Cells" (http://online.liebertpub.com/doi/full/10.1089/biores.2012.0235) reports that when grown in culture with high levels of glucose and B27, these SSEA4+ stem cells can differentiate into insulin-producing pancreatic cells.

###

About the Journal

BioResearch Open Access (http://www.liebertpub.com/biores) is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available online at the BioResearch Open Access website (http://www.liebertpub.com/biores).

About the Publisher

Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website (http://www.liebertpub.com).

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

More:
New marker for identifying precursors to insulin-producing cells in pancreas